Condition
Ph+ Acute Lymphoblastic Leukemia (Ph+ALL)
Total Trials
3
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (2)
Trial Status
Not Yet Recruiting2
Withdrawn1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07493408Phase 2Not Yet RecruitingPrimary
Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML
NCT06658925Phase 2Not Yet RecruitingPrimary
Olverembatinib as Maintenance Therapy or Preemptive Therapy After Allo-HSCT in Ph+ALL
NCT03414450Phase 1Withdrawn
Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies
Showing all 3 trials